drugset / Trial / NCT00781274
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
Phase 3
Completed
32 enrolled
Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.
Timeline
- Start
- 2008-12
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telaprevir | Small molecule | 750 mg | — |
| Background | Peginterferon alfa-2b | Protein / enzyme biologic | 1.5 ug/kg | — |
| Background | Ribavirin | Small molecule | 600 mg | — |
| Background | Ribavirin | Small molecule | 1000 mg | — |